GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (FRA:49Y) » Definitions » Investments And Advances

Avenue Therapeutics (FRA:49Y) Investments And Advances : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Avenue Therapeutics Investments And Advances?

Avenue Therapeutics's Investments And Advances for the quarter that ended in Mar. 2025 was €0.00 Mil.


Avenue Therapeutics Investments And Advances Historical Data

The historical data trend for Avenue Therapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics Investments And Advances Chart

Avenue Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avenue Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Avenue Therapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Avenue Therapeutics Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its current product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders.

Avenue Therapeutics Headlines

No Headlines